Cargando…

Urinary Tissue Inhibitor of Metalloproteinase-2 (TIMP-2) • Insulin-Like Growth Factor-Binding Protein 7 (IGFBP7) Predicts Adverse Outcome in Pediatric Acute Kidney Injury

BACKGROUND: The G1 cell cycle inhibitors tissue inhibitor of metalloproteinase-2 (TIMP-2) and insulin-like growth factor-binding protein 7 (IGFBP7) have been identified as promising biomarkers for the prediction of adverse outcomes including renal replacement therapy (RRT) and mortality in criticall...

Descripción completa

Detalles Bibliográficos
Autores principales: Westhoff, Jens H., Tönshoff, Burkhard, Waldherr, Sina, Pöschl, Johannes, Teufel, Ulrike, Westhoff, Timm H., Fichtner, Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4659607/
https://www.ncbi.nlm.nih.gov/pubmed/26606754
http://dx.doi.org/10.1371/journal.pone.0143628
_version_ 1782402651090059264
author Westhoff, Jens H.
Tönshoff, Burkhard
Waldherr, Sina
Pöschl, Johannes
Teufel, Ulrike
Westhoff, Timm H.
Fichtner, Alexander
author_facet Westhoff, Jens H.
Tönshoff, Burkhard
Waldherr, Sina
Pöschl, Johannes
Teufel, Ulrike
Westhoff, Timm H.
Fichtner, Alexander
author_sort Westhoff, Jens H.
collection PubMed
description BACKGROUND: The G1 cell cycle inhibitors tissue inhibitor of metalloproteinase-2 (TIMP-2) and insulin-like growth factor-binding protein 7 (IGFBP7) have been identified as promising biomarkers for the prediction of adverse outcomes including renal replacement therapy (RRT) and mortality in critically ill adult patients who develop acute kidney injury (AKI). However, the prognostic value of urinary TIMP-2 and IGFBP7 in neonatal and pediatric AKI for adverse outcome has not been investigated yet. METHODS: The product of the urinary concentration of TIMP-2 and IGFBP7 ([TIMP-2]•[IGFBP7]) was assessed by a commercially available immunoassay (NephroCheck(™)) in a prospective cohort study in 133 subjects aged 0–18 years including 46 patients with established AKI according to pRIFLE criteria, 27 patients without AKI (non-AKI group I) and 60 apparently healthy neonates and children (non-AKI group II). AKI etiologies were: dehydration/hypovolemia (n = 7), hemodynamic instability (n = 7), perinatal asphyxia (n = 9), septic shock (n = 7), typical hemolytic-uremic syndrome (HUS; n = 5), interstitial nephritis (n = 5), vasculitis (n = 4), nephrotoxic injury (n = 1) and renal vein thrombosis (n = 1). RESULTS: When AKI patients were classified into pRIFLE criteria, 6/46 (13%) patients fulfilled the criteria for the category “Risk”, 13/46 (28%) for “Injury”, 26/46 (57%) for “Failure” and 1/46 (2%) for “Loss”. Patients in the “Failure” stage had a median 3.7-fold higher urinary [TIMP-2]•[IGFBP7] compared to non-AKI subjects (P<0.001). When analyzed for AKI etiology, highest [TIMP-2]•[IGFBP7] values were found in patients with septic shock (P<0.001 vs. non-AKI I+II). Receiver operating characteristic (ROC) curve analyses in the AKI group revealed good performance of [TIMP-2]•[IGFBP7] in predicting 30-day (area under the curve (AUC) 0.79; 95% CI, 0.61–0.97) and 3-month mortality (AUC 0.84; 95% CI, 0.67–0.99) and moderate performance in predicting RRT (AUC 0.67; 95% CI, 0.50–0.84). CONCLUSIONS: This study shows that urinary [TIMP-2]•[IGFBP7] has a good diagnostic performance in predicting adverse outcomes in neonatal and pediatric AKI of heterogeneous etiology.
format Online
Article
Text
id pubmed-4659607
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-46596072015-12-02 Urinary Tissue Inhibitor of Metalloproteinase-2 (TIMP-2) • Insulin-Like Growth Factor-Binding Protein 7 (IGFBP7) Predicts Adverse Outcome in Pediatric Acute Kidney Injury Westhoff, Jens H. Tönshoff, Burkhard Waldherr, Sina Pöschl, Johannes Teufel, Ulrike Westhoff, Timm H. Fichtner, Alexander PLoS One Research Article BACKGROUND: The G1 cell cycle inhibitors tissue inhibitor of metalloproteinase-2 (TIMP-2) and insulin-like growth factor-binding protein 7 (IGFBP7) have been identified as promising biomarkers for the prediction of adverse outcomes including renal replacement therapy (RRT) and mortality in critically ill adult patients who develop acute kidney injury (AKI). However, the prognostic value of urinary TIMP-2 and IGFBP7 in neonatal and pediatric AKI for adverse outcome has not been investigated yet. METHODS: The product of the urinary concentration of TIMP-2 and IGFBP7 ([TIMP-2]•[IGFBP7]) was assessed by a commercially available immunoassay (NephroCheck(™)) in a prospective cohort study in 133 subjects aged 0–18 years including 46 patients with established AKI according to pRIFLE criteria, 27 patients without AKI (non-AKI group I) and 60 apparently healthy neonates and children (non-AKI group II). AKI etiologies were: dehydration/hypovolemia (n = 7), hemodynamic instability (n = 7), perinatal asphyxia (n = 9), septic shock (n = 7), typical hemolytic-uremic syndrome (HUS; n = 5), interstitial nephritis (n = 5), vasculitis (n = 4), nephrotoxic injury (n = 1) and renal vein thrombosis (n = 1). RESULTS: When AKI patients were classified into pRIFLE criteria, 6/46 (13%) patients fulfilled the criteria for the category “Risk”, 13/46 (28%) for “Injury”, 26/46 (57%) for “Failure” and 1/46 (2%) for “Loss”. Patients in the “Failure” stage had a median 3.7-fold higher urinary [TIMP-2]•[IGFBP7] compared to non-AKI subjects (P<0.001). When analyzed for AKI etiology, highest [TIMP-2]•[IGFBP7] values were found in patients with septic shock (P<0.001 vs. non-AKI I+II). Receiver operating characteristic (ROC) curve analyses in the AKI group revealed good performance of [TIMP-2]•[IGFBP7] in predicting 30-day (area under the curve (AUC) 0.79; 95% CI, 0.61–0.97) and 3-month mortality (AUC 0.84; 95% CI, 0.67–0.99) and moderate performance in predicting RRT (AUC 0.67; 95% CI, 0.50–0.84). CONCLUSIONS: This study shows that urinary [TIMP-2]•[IGFBP7] has a good diagnostic performance in predicting adverse outcomes in neonatal and pediatric AKI of heterogeneous etiology. Public Library of Science 2015-11-25 /pmc/articles/PMC4659607/ /pubmed/26606754 http://dx.doi.org/10.1371/journal.pone.0143628 Text en © 2015 Westhoff et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Westhoff, Jens H.
Tönshoff, Burkhard
Waldherr, Sina
Pöschl, Johannes
Teufel, Ulrike
Westhoff, Timm H.
Fichtner, Alexander
Urinary Tissue Inhibitor of Metalloproteinase-2 (TIMP-2) • Insulin-Like Growth Factor-Binding Protein 7 (IGFBP7) Predicts Adverse Outcome in Pediatric Acute Kidney Injury
title Urinary Tissue Inhibitor of Metalloproteinase-2 (TIMP-2) • Insulin-Like Growth Factor-Binding Protein 7 (IGFBP7) Predicts Adverse Outcome in Pediatric Acute Kidney Injury
title_full Urinary Tissue Inhibitor of Metalloproteinase-2 (TIMP-2) • Insulin-Like Growth Factor-Binding Protein 7 (IGFBP7) Predicts Adverse Outcome in Pediatric Acute Kidney Injury
title_fullStr Urinary Tissue Inhibitor of Metalloproteinase-2 (TIMP-2) • Insulin-Like Growth Factor-Binding Protein 7 (IGFBP7) Predicts Adverse Outcome in Pediatric Acute Kidney Injury
title_full_unstemmed Urinary Tissue Inhibitor of Metalloproteinase-2 (TIMP-2) • Insulin-Like Growth Factor-Binding Protein 7 (IGFBP7) Predicts Adverse Outcome in Pediatric Acute Kidney Injury
title_short Urinary Tissue Inhibitor of Metalloproteinase-2 (TIMP-2) • Insulin-Like Growth Factor-Binding Protein 7 (IGFBP7) Predicts Adverse Outcome in Pediatric Acute Kidney Injury
title_sort urinary tissue inhibitor of metalloproteinase-2 (timp-2) • insulin-like growth factor-binding protein 7 (igfbp7) predicts adverse outcome in pediatric acute kidney injury
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4659607/
https://www.ncbi.nlm.nih.gov/pubmed/26606754
http://dx.doi.org/10.1371/journal.pone.0143628
work_keys_str_mv AT westhoffjensh urinarytissueinhibitorofmetalloproteinase2timp2insulinlikegrowthfactorbindingprotein7igfbp7predictsadverseoutcomeinpediatricacutekidneyinjury
AT tonshoffburkhard urinarytissueinhibitorofmetalloproteinase2timp2insulinlikegrowthfactorbindingprotein7igfbp7predictsadverseoutcomeinpediatricacutekidneyinjury
AT waldherrsina urinarytissueinhibitorofmetalloproteinase2timp2insulinlikegrowthfactorbindingprotein7igfbp7predictsadverseoutcomeinpediatricacutekidneyinjury
AT poschljohannes urinarytissueinhibitorofmetalloproteinase2timp2insulinlikegrowthfactorbindingprotein7igfbp7predictsadverseoutcomeinpediatricacutekidneyinjury
AT teufelulrike urinarytissueinhibitorofmetalloproteinase2timp2insulinlikegrowthfactorbindingprotein7igfbp7predictsadverseoutcomeinpediatricacutekidneyinjury
AT westhofftimmh urinarytissueinhibitorofmetalloproteinase2timp2insulinlikegrowthfactorbindingprotein7igfbp7predictsadverseoutcomeinpediatricacutekidneyinjury
AT fichtneralexander urinarytissueinhibitorofmetalloproteinase2timp2insulinlikegrowthfactorbindingprotein7igfbp7predictsadverseoutcomeinpediatricacutekidneyinjury